SCHEMBL4201309

SCHEMBL4201309

CC(C)(C)OC(=O)N1CCc2ccc(N3CCC(F)(F)CC3)nc2CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.44
ESR2 Q92731 1/20 0.44
MAPT P10636 2/20 0.44
GPR119 Q8TDV5 5/20 0.43
NR1H2 P55055 1/20 0.43
CKS1B P61024 2/20 0.41
SKP1 P63208 2/20 0.41
SKP2 Q13309 2/20 0.41
AVPR1A P37288 2/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
CYP11B2 P19099 1/20 0.39
IDH1 O75874 1/20 0.39
IDH2 P48735 1/20 0.39
KIF18A Q8NI77 1/20 0.38
GRM5 P41594 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4196469 0.96 MAP4K4 (0.42) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL21042251 0.90 ESR2 (0.45) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL4205087 0.88 MAP4K4 (0.48) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL4213013 0.86 MAP4K4 (0.47) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL13568089 0.86 MAP4K4 (0.50) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL4203740 0.86 MAP4K4 (0.47) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL4196360 0.86 GPR119 (0.51) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL8054507 0.84 MAP4K4 (0.51) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL4215873 0.84 MAP4K4 (0.51) MAP4K4ESR2MAPTGPR119NR1H2
SCHEMBL4015179 0.84 MAP4K4 (0.46) MAP4K4ESR2MAPTGPR119NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS HTR2C, HTR2A, HTR5A MAP4K4 3097/4885ESR2 550/4885MAPT 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.